MedTrace Logo

Safety Study of TRK-820 for Patient With Hemodialysis

NCT01248650 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2010-11-25

No results posted yet for this study

Summary

The purpose of this study is to observe pharmacokinetics and safety of nalfurafine hydrochloride in patients receiving hemodialysis.

Conditions

  • Chronic Renal Failure

Interventions

DRUG

nalfurafine hydrochloride

Sponsors & Collaborators

  • Toray Industries, Inc

    collaborator INDUSTRY

  • SK Chemicals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wooseong Huh, MD, PhD · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01248650 on ClinicalTrials.gov